Biogen wins FDA approval for high-dose SPINRAZA regimen in spinal muscular atrophy
Biogen (NASDAQ:BIIB) said the FDA approved a higher-dose regimen of its SPINRAZA (nusinersen) therapy for patients with spinal muscular atrophy (SMA).
Biogen (NASDAQ:BIIB) said the FDA approved a higher-dose regimen of its SPINRAZA (nusinersen) therapy for patients with spinal muscular atrophy (SMA).
Vor Bio (NASDAQ:VOR) has secured a $75 million private placement with TCGX, a transaction executed on March 27, 2026, that significantly bolsters the company's balance sheet.
Eikon Therapeutics (NASDAQ:EIKN), a clinical-stage biotechnology company focused on developing novel medicines through advanced imaging and machine learning platforms, reported corporate and clinical updates on March 30, 2026, alongside its full-year 2025 financial results.
Functional Brands (NASDAQ:MEHA), a leading developer and manufacturer of functional health and wellness products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Rezolve Ai (NASDAQ:RZLV), a global leader in AI-powered conversational commerce and retail engagement, today announced its financial results for the full year ended December 31, 2025.
Uber Technologies (NYSE:UBER) today announced a definitive agreement to acquire Blacklane, a premier global chauffeur service, marking a significant escalation in Uber’s strategy to dominate the high-margin luxury and corporate travel segments
Soluna Holdings (NASDAQ:SLNH), a specialized developer of green data centers for intensive computing applications such as Bitcoin mining and artificial intelligence, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Terrestrial Energy (NASDAQ:IMSR), a developer of Generation IV advanced nuclear technology, today announced its financial results and program milestones for the fourth quarter and full year ended December 31, 2025.
Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
USA Rare Earth (NASDAQ:USAR) reported a transformative shift in its financial position and operational footprint for the full year 2025, underpinned by a massive capital injection that establishes the company as a primary contender in the race to build a non-Chinese permanent magnet supply chain.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
